MWM
IBRX icon

Maltin Wealth Management’s ImmunityBio IBRX Stock Holding History

Maltin Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Hold
13,150
– – 0.04% 144
2026
Q1 		$101K Hold
13,150
– – 0.04% 135
2025
Q4 		$26K Hold
13,150
– – 0.01% 132
2025
Q3 		$32.3K Buy
+13,150
New +$33.9K 0.01% 131

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Maltin Wealth Management's IBRX Position: Q2 2026 in Review

Maltin Wealth Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 13,150 shares worth $115K. The position accounts for 0.04% of the portfolio, ranked #144.

Maltin Wealth Management first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Maltin Wealth Management held 13,150 shares of ImmunityBio worth $115K as of Q2 2026.
  • Maltin Wealth Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.04% of Maltin Wealth Management's portfolio in Q2 2026, its #144 holding.
  • Maltin Wealth Management first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Maltin Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.